SciGen Limited, a company headquartered in Singapore but listed in Australia, received SFDA approval to begin marketing its recombinant human insulin product, SciLin, in China.  The company will outsource distribution of the product to Shenzhen Meheco and Hefei Life Sciences Technology (HLST).  They have committed themselves to selling $17 million of SciLin in its first three years on the market. More details...

Stock Symbol:  (ASX: SIE)